JP2002531527A5 - - Google Patents

Download PDF

Info

Publication number
JP2002531527A5
JP2002531527A5 JP2000586368A JP2000586368A JP2002531527A5 JP 2002531527 A5 JP2002531527 A5 JP 2002531527A5 JP 2000586368 A JP2000586368 A JP 2000586368A JP 2000586368 A JP2000586368 A JP 2000586368A JP 2002531527 A5 JP2002531527 A5 JP 2002531527A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000586368A
Other versions
JP3805625B2 (ja
JP2002531527A (ja
Filing date
Publication date
Priority claimed from GBGB9826882.4A external-priority patent/GB9826882D0/en
Application filed filed Critical
Publication of JP2002531527A publication Critical patent/JP2002531527A/ja
Publication of JP2002531527A5 publication Critical patent/JP2002531527A5/ja
Application granted granted Critical
Publication of JP3805625B2 publication Critical patent/JP3805625B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000586368A 1998-12-07 1999-12-06 マクロライドの安定化 Expired - Lifetime JP3805625B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9826882.4 1998-12-07
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds
GB9904934.8 1999-03-04
PCT/EP1999/009521 WO2000033878A2 (en) 1998-12-07 1999-12-06 Stabilization of macrolides

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005106512A Division JP5043308B2 (ja) 1998-12-07 2005-04-01 マクロライドの安定化
JP2005378514A Division JP5165199B2 (ja) 1998-12-07 2005-12-28 マクロライドの安定化

Publications (3)

Publication Number Publication Date
JP2002531527A JP2002531527A (ja) 2002-09-24
JP2002531527A5 true JP2002531527A5 (ja) 2005-12-22
JP3805625B2 JP3805625B2 (ja) 2006-08-02

Family

ID=26314797

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000586368A Expired - Lifetime JP3805625B2 (ja) 1998-12-07 1999-12-06 マクロライドの安定化
JP2005106512A Expired - Lifetime JP5043308B2 (ja) 1998-12-07 2005-04-01 マクロライドの安定化
JP2005378514A Expired - Lifetime JP5165199B2 (ja) 1998-12-07 2005-12-28 マクロライドの安定化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2005106512A Expired - Lifetime JP5043308B2 (ja) 1998-12-07 2005-04-01 マクロライドの安定化
JP2005378514A Expired - Lifetime JP5165199B2 (ja) 1998-12-07 2005-12-28 マクロライドの安定化

Country Status (38)

Country Link
US (5) US6605613B2 (ja)
EP (4) EP2269651A3 (ja)
JP (3) JP3805625B2 (ja)
KR (2) KR20060096477A (ja)
CN (2) CN1876657B (ja)
AR (3) AR026102A1 (ja)
AT (1) ATE365051T1 (ja)
AU (1) AU759219B2 (ja)
BE (1) BE1012869A3 (ja)
BR (1) BR9915986A (ja)
CA (3) CA2651609A1 (ja)
CO (1) CO4980847A1 (ja)
CY (1) CY1106870T1 (ja)
CZ (2) CZ302210B6 (ja)
DE (1) DE69936352T3 (ja)
DK (1) DK1137439T4 (ja)
ES (1) ES2288033T5 (ja)
FR (1) FR2786771B1 (ja)
GB (2) GB9826882D0 (ja)
HK (1) HK1038889B (ja)
HU (2) HU230174B1 (ja)
ID (1) ID29250A (ja)
IL (1) IL143092A0 (ja)
IT (1) IT1319701B1 (ja)
MY (2) MY127579A (ja)
NO (2) NO332698B1 (ja)
NZ (2) NZ511936A (ja)
PE (1) PE20001333A1 (ja)
PL (2) PL196627B1 (ja)
PT (1) PT1137439E (ja)
RU (1) RU2243769C2 (ja)
SG (1) SG151072A1 (ja)
SI (1) SI1137439T2 (ja)
SK (2) SK287325B6 (ja)
TR (2) TR200101416T2 (ja)
TW (2) TWI248938B (ja)
WO (1) WO2000033878A2 (ja)
ZA (1) ZA200104360B (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7432074B2 (en) 2002-02-13 2008-10-07 TEVA Gyógyszergyár Zártkörüen MüködöRészvénytársaság Method for extracting a macrolide from biomatter
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
SI1553940T1 (sl) 2002-07-30 2008-08-31 Wyeth Corp Parenteralne farmacevtske oblike, ki vsebujejo rapamicin-hidroksiester
WO2004089958A2 (en) * 2003-03-31 2004-10-21 TEVA Gyógyszergyár Részvénytársaság Crystallization and purification of macrolides
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
PT1558622E (pt) 2003-07-24 2007-12-04 Teva Gyogyszergyar Zartkoeruee Processo de purificação de macrolidos
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
KR20060126701A (ko) * 2003-12-10 2006-12-08 애크럭스 디디에스 피티와이 리미티드 경피 또는 국소 약물 전달에 따른 원치않는 효과의치료방법
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
CN101076319A (zh) * 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
KR20080077989A (ko) * 2005-12-20 2008-08-26 와이어쓰 약물의 불순물 조절을 통한 ｃｃｉ-779 제형의 안정성 조절
EP2001438A2 (en) * 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
US20120165260A2 (en) * 2010-06-07 2012-06-28 Telik, Inc. Crystalline ezatiostat hydrochloride ansolvate
CN103140494A (zh) * 2010-08-04 2013-06-05 美利奴生命科学有限公司 制备具有抗增殖特性的新的42-o-（杂烷氧基烷基）雷帕霉素化合物的方法
US9079921B2 (en) 2010-11-19 2015-07-14 Biocon Limited Processes for preparation of Everolimus and intermediates thereof
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (ja) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
WO2017018433A1 (ja) 2015-07-28 2017-02-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物及びその製造方法
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
EP3351245A4 (en) * 2015-09-18 2019-05-22 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
EP3466424A1 (en) 2016-05-27 2019-04-10 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprizing rapamycin or derivative thereof
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
US11814397B2 (en) 2020-03-27 2023-11-14 Boston Scientific Scimed, Inc. Methods for crystallization of drugs
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) * 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
SG47580A1 (en) 1992-10-13 1998-04-17 American Home Prod Carbamates of rapamycin
BR9609260A (pt) * 1995-06-09 1999-05-18 Novartis Ag Derivados de rapamicina
FR2736550B1 (fr) * 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
PT1208847E (pt) * 1996-07-30 2007-07-24 Novartis Ag Composições farmacêuticas para o tratamento da rejeição de transplantes, doenças autoimunes ou inflamatórias compreendendo ciclosporina a e 40-0-(2-hidroxietil)-rapamicina
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
AU6041498A (en) 1997-02-04 1998-08-25 Abbott Laboratories Pain reducing parenteral liposome formulation

Similar Documents

Publication Publication Date Title
BE2018C020I2 (ja)
BE2015C057I2 (ja)
BE2016C007I2 (ja)
BE2015C018I2 (ja)
BE2014C017I2 (ja)
BE2013C051I2 (ja)
BE2013C001I2 (ja)
BE2012C036I2 (ja)
BE2011C004I2 (ja)
BE2010C011I2 (ja)
BE2008C046I2 (ja)
BE1025464I2 (ja)
BRPI0017527B8 (ja)
JP2002508994A5 (ja)
IN2001KO01233A (ja)
JP2002524356A5 (ja)
BE2008C047I2 (ja)
JP2002531720A5 (ja)
BRPI0001672A2 (ja)
JP2002504431A5 (ja)
JP2002522685A5 (ja)
JP2002512891A5 (ja)
JP2002518463A5 (ja)
BRPI0001542A2 (ja)
JP2002531527A5 (ja)